Related Experiment Video

Updated: Jul 19, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Folate receptor-mediated cancer cell specific gene delivery using folic acid-conjugated oligochitosans

Dongwon Lee1, Richard Lockey, Shyam Mohapatra

  • 1Department of Internal Medicine, Division of Allergy and Immunology, Joy McCann Culverhouse Airway Disease Center, University of South Florida, College of Medicine, James A. Haley Veteran's Hospital, Tampa, FI 33612, USA.

Journal of Nanoscience and Nanotechnology
|October 20, 2006
PubMed

Insights

Folic acid-conjugated chitosan nanoparticles enhance gene delivery to cancer cells by targeting folate receptors. This biocompatible carrier shows promise for improved cancer gene therapy applications.

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Molecular Biology

Background:

  • Chitosan is a promising biomaterial for gene delivery, but suffers from low transfection efficiency and poor target specificity.
  • Targeted gene delivery systems are crucial for effective cancer therapy, aiming to deliver therapeutic DNA specifically to cancer cells.
  • Folate receptors are overexpressed on various cancer cells, making them an attractive target for cancer-specific drug and gene delivery.

Purpose of the Study:

  • To develop and characterize folic acid-conjugated chitosan nanoparticles (FACN) for targeted gene delivery to folate receptor-overexpressing cancer cells.
  • To evaluate the in vitro gene transfer efficiency and specificity of FACN compared to unmodified chitosan.
  • To confirm the mechanism of targeted gene delivery via folate receptor-mediated endocytosis.

Main Methods:

  • Synthesis and characterization of folic acid-conjugated chitosan (FACN) using 1H-NMR.
  • Evaluation of in vitro gene transfer potential of FACN/pDNA nanocomplexes in human epithelial ovarian cancer OV2008 and human breast cancer MCF-7 cells.
  • Assessment of competitive inhibition of transfection by free folic acid to determine targeting specificity.

Main Results:

  • FACN was successfully synthesized, characterized, and demonstrated biocompatibility.
  • FACN at a 10:1 weight ratio significantly enhanced gene transfer efficiency in folate receptor-overexpressing cancer cells compared to unmodified chitosan (p < 0.01).
  • Transfection mediated by FACN/pDNA nanocomplexes was competitively inhibited by free folic acid, confirming folate receptor-specific uptake.

Conclusions:

  • Folic acid conjugation to chitosan creates an effective targeting ligand for cancer cells.
  • FACN nanoparticles offer significantly improved gene transfer efficiency and target specificity for cancer gene therapy.
  • FACN represents a promising biocompatible carrier for developing advanced cancer gene therapy strategies.

More Related Videos

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...